Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SGN-15 and Docetaxel Dosing Schedule in Advanced NSCLC
NCT00086333Phase 2Completed
- Sponsor
- Seagen Inc.
- Start
- Jul 2004
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of SGN-15 in non-small cell lung carcinoma (NSCLC), sponsored by Seagen Inc.. Started Jul 2004; status: completed.
02
Drugs
SGN-15
03
Conditions
non-small cell lung carcinoma (NSCLC)
Beyond the preview
Go deeper on NCT00086333.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00086333.